Case Series on the Efficacy and Safety of Tocilizumab in IVIG-Resistant Kawasaki Disease: A Retrospective Analysis of Five Patients
Tocilizumab effectively controls systemic inflammation and improves coronary artery outcomes in IVIG-resistant KD patients, with no observed adverse events. Larger studies are necessary to confirm these findings and further investigate long-term effects on coronary artery health.
Authors
- Qingfang Zhou
- Fang Xie (ORCID: https://orcid.org/0000-0002-2177-2283)
- Xiaohui Liu (ORCID: https://orcid.org/0000-0001-7391-5058)
- Wei Zhao (ORCID: https://orcid.org/0000-0003-0319-1722)
- Qian Ouyang
- Lin Li (ORCID: https://orcid.org/0000-0002-2027-0871)
- Jiayun Ling (ORCID: https://orcid.org/0000-0001-6572-4980)
Institutions
- Jiangxi Provincial Children's Hospital (CN)
Publication Details
- Journal
- Journal of Inflammation Research
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/jir.s479879
- Citations
- 6
- Primary Topic
- Kawasaki Disease and Coronary Complications
- Type
- article
- Field-Weighted Citation Impact
- 3.44